AddLife enters 2026 with improved profitability, a strong balance sheet, and increased acquisition activity, while maintaining positive EBITA margin development. The company leverages a European footprint spanning multiple countries to serve publicly funded healthcare, research institutions, and pharmaceutical sectors, positioning itself as a specialized provider in diagnostics, biomedical research, and medical device solutions.
Cyborg Score Rationale
AddLife enters 2026 with improved profitability and strong balance sheet, alongside increased acquisition activity. The company benefits from a long operational history, diversified geographic presence, and recurring revenue from healthcare and research sectors. However, its mid-sized market capitalization and exposure to healthcare spending cycles present some volatility.